RT Journal Article
T1 Association of ABO and Rh blood groups with obstetric outcomes in SARS-CoV-2 infected pregnancies: A prospective study with a multivariate analysis
A1 Sainz Bueno, Jose Antonio
A1 Cerrillos Gonzalez, Lucas
A1 Abascal-Saiz, Alejandra
A1 Rodriguez Gallego, Maria Victoria
A1 Lopez Perez, Rocio
A1 Fernandez Alonso, Ana Maria
A1 de la Cruz Conty, Maria Luisa
A1 Alonso Saiz, Ruben
A1 Molina Oller, Magdalena
A1 Santamaria Ortiz, Amparo
A1 Martinez-Perez, Oscar
A1 Spanish Obstetric Emergency Grp, 
K1 ABO blood group
K1 Coronavirus
K1 SARS-CoV-2
K1 COVID-19
K1 Pregnancy
K1 Disease susceptibility
K1 Maternal morbidity
K1 Age
AB Objective: To evaluate the influence of ABO and Rh blood groups on morbidity among SARS-CoV-2 infected pregnancies.Design: Prospective observational study.Setting: 78 centers of the Spanish Obstetric Emergency Group.Population: Pregnant women with SARS-CoV-2 tested with polymerase-chain-reaction between 26-February and 5-November 2020. A cohort of 1278 SARS-CoV-2(+) pregnant women was analyzed and a concurrent comparison group of 1453 SARS-COV-2 patients was established.Methods: Data were collected from medical charts. SARS-COV-2(+) was compared with SARS-COV-2(-) for differences in distribution of blood groups. We performed multivariate analysis, controlling for maternal age and ethnicity, to evaluate association of ABO and Rh blood groups with maternal and perinatal outcomes in SARS-CoV-2(+) patients with adjusted odds ratios (aOR) and 95% confidence intervals (CI).Main outcomes measures: Medical morbidity: Symptomatic COVID-19 and medical complications. Obstetric outcomes: caesarean delivery, preterm deliveries, preterm premature rupture of membranes (PPROM), hemorrhagic events, pre-eclampsia, maternal and neonatal mortality, stillbirth.Results: Differences were noted between blood types and Rh for age and ethnicity comparing SARS-CoV-2 (+) and SARS-CoV-2(-) groups (p
PB Elsevier
SN 0301-2115
YR 2021
FD 2021-07-13
LK https://hdl.handle.net/10668/24906
UL https://hdl.handle.net/10668/24906
LA en
DS RISalud
RD Apr 5, 2025